Drug Insights

Synapse Simplified: How to Find Donepezil Information

29 February 2024
2 min read

Donepezil, a minuscule molecular compound, functions as an acetylcholinesterase inhibitor, indicating that it hinders the degradation of acetylcholine, a neurotransmitter in the brain, and provides assistance in enhancing cognitive function. Patients in mild, moderate, and severe stages of Alzheimer's Disease receive this drug as a therapeutic agent. Initially authorized in November 1996 by Eisai, a pharmaceutical establishment situated in Japan, it has now expanded to a worldwide availability. Although Donepezil Hydrochloride does not hold the cure for Alzheimer's Disease, it does assist in controlling some of the symptoms associated with the disease, such as memory loss, confusion, and other cognitive impairments. As a crucial medication for those existing with Alzheimer's Disease, it can amplify their quality of life and curtail the progression of the disease. Click on the image below to begin the exploration journey of Donepezil through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Encoded Therapeutics Gains UK Approval for ETX101 Gene Therapy Trial in Dravet Syndrome
Latest Hotspot
3 min read
Encoded Therapeutics Gains UK Approval for ETX101 Gene Therapy Trial in Dravet Syndrome
29 February 2024
Encoded Therapeutics Receives UK Regulatory Nod for Experimental Gene Treatment ETX101 Aimed at Dravet Syndrome.
Read →
A Complete Guide to Searching Phenylephrine on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Phenylephrine on Synapse
29 February 2024
Phenylephrine, a small drug molecule, acts as an alpha-1 adrenergic receptor agonist to help dilate the pupil for eye exams and surgeries.
Read →
Oscotec/Adel Begins Phase 1 Trial of ADEL-Y01 Anti-Tau Antibody for Alzheimer's
Latest Hotspot
3 min read
Oscotec/Adel Begins Phase 1 Trial of ADEL-Y01 Anti-Tau Antibody for Alzheimer's
29 February 2024
Oscotec/Adel has commenced the initial human administration phase of their Phase 1 trial, testing the anti-tau antibody ADEL-Y01 as a potential treatment for Alzheimer's.
Read →
Erdafitinib: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Erdafitinib: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
29 February 2024
TAR-210 is an intravesical drug delivery system that is designed to provide local, continuous release of erdafitinib.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.